These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 9047204)

  • 1. Platelet-derived thromboxane A2 decreases microvascular perfusion after arterial repair.
    O'Shaughnessy M; Anderson GL; Acland RD; Barker JH
    Plast Reconstr Surg; 1997 Mar; 99(3):834-41. PubMed ID: 9047204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of thromboxane A2 in the altered microvascular reactivity in two-kidney, one-clip hypertension.
    Carvalho MH; Fortes ZB; Nigro D; Oliveira MA; Scivoletto R
    Endothelium; 1997; 5(3):167-78. PubMed ID: 9272380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined thromboxane A2 synthase inhibition and prostaglandin endoperoxide receptor antagonism limits myocardial infarct size after mechanical coronary occlusion and reperfusion at doses enhancing coronary thrombolysis by streptokinase.
    Vandeplassche G; Hermans C; Somers Y; Van de Werf F; de Clerck F
    J Am Coll Cardiol; 1993 Apr; 21(5):1269-79. PubMed ID: 8459087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A2 receptor antagonism and synthase inhibition in essential hypertension.
    Ritter JM; Barrow SE; Doktor HS; Stratton PD; Edwards JS; Henry JA; Gould S
    Hypertension; 1993 Aug; 22(2):197-203. PubMed ID: 8340155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of thromboxane A2 synthase inhibition, singly or combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on occlusive thrombosis elicited by endothelial cell injury or by deep vascular damage in canine coronary arteries.
    Vandeplassche G; Hemans C; Van de Water A; Xhonneux R; Wouters L; Van Ammel K; De Clerck F
    Circ Res; 1991 Aug; 69(2):313-24. PubMed ID: 1830517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of heparin and dietary fish oil on embolic events and the microcirculation downstream from a small-artery repair.
    Barker JH; Gu JM; Anderson GL; O'Shaughnessy M; Pierangeli S; Johnson P; Galletti G; Acland RD
    Plast Reconstr Surg; 1993 Feb; 91(2):335-43. PubMed ID: 8430150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ridogrel, a thromboxane synthase inhibitor and receptor antagonist, on blood pressure in the spontaneously hypertensive rat.
    Quest DW; Wilson TW
    Jpn J Pharmacol; 1998 Dec; 78(4):479-86. PubMed ID: 9920205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridogrel: a selective inhibitor of the cytochrome P450-dependent thromboxane synthesis.
    Vanden Bossche H; Willemsens G; Bellens D; Janssen PA
    Biochem Pharmacol; 1992 Feb; 43(4):739-44. PubMed ID: 1540227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ridogrel, a new platelet antiaggregant molecule with a double mechanism of action. A pharmacological and clinical profile].
    Di Perri T; Notari M; Assogna G
    Recenti Prog Med; 1991 Oct; 82(10):533-40. PubMed ID: 1759039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects.
    Naran NH; Chetty N
    Thromb Res; 1997 Dec; 88(5):399-407. PubMed ID: 9556227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2/prostaglandin endoperoxide receptors upon chronic administration to man.
    Weber C; Beetens JR; Tegtmeier F; Van Rooy P; Vercammen E; Wouters L; De Clerck F
    Thromb Haemost; 1992 Aug; 68(2):214-20. PubMed ID: 1412169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries.
    Bourgain RH; Andries R; Decuyper K; De Clerck F
    J Lipid Mediat; 1991; 3(1):3-11. PubMed ID: 1837488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease.
    Hoet B; Arnout J; Van Geet C; Deckmyn H; Verhaeghe R; Vermylen J
    Thromb Haemost; 1990 Aug; 64(1):87-90. PubMed ID: 2148849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
    Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
    J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of thromboxane A2 in the mediation of the contractile effect induced by inhibition of nitric oxide synthesis in isolated rat middle cerebral arteries.
    Benyó Z; Görlach C; Wahl M
    J Cereb Blood Flow Metab; 1998 Jun; 18(6):616-8. PubMed ID: 9626185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a combined administration of ridogrel and ketanserin in patients with intermittent claudication.
    De Cree J; Geukens H; Gutwirth P; De Clerck F; Vercammen E; Verhaegen H
    Int Angiol; 1993 Mar; 12(1):59-68. PubMed ID: 8376914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.